▎WuXiEdited by Kant Content Team

Recently, AstraZeneca's supplemental Biologics License Application (sBLA) for the needle-free nasal spray FluMist Quadrivalent (live attenuated influenza vaccine, nasal spray) has been accepted by the U.S. FDA. The sBLA seeks FDA approval for FluMist Quadrivalent to be self-administered by patients or administered by caregivers.If approved, FluMist Quadrivalent will become the first influenza vaccine that can be self-administered by eligible patients or administered by caregivers, adding a new option for influenza vaccination.

Influenza is a contagious respiratory disease caused by the influenza virus, which can lead to severe complications in certain populations, such as people aged 65 and above, young children, and individuals with certain health conditions.

FluMist Quadrivalent is a live attenuated vaccine administered as a nasal spray to prevent influenza.This vaccine contains four screened attenuated influenza virus strains, which are able to replicate on the nasal mucosa, causing a minor infection. This infection triggers both mucosal and systemic immune responses.The vaccine was first approved in the United States in 2003 for use in children and adults aged 2 to 49.The approval of this vaccine provides an important precedent for the development of nasal spray vaccines, proving that mucosal immune responses can offer protection.Use.This vaccine is one of the influenza vaccines recommended by the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP).

This sBLA was supported by an usability study, which confirmed,Individuals aged 18 and above can self-administer FluMist Quadrivalent or administer it to eligible patients aged 2-49 without any additional instructions. There is substantial data indicating that the efficacy and safety of FluMist Quadrivalent are comparable to other influenza vaccines.

FluMist Quadrivalent is currently under review by the U.S. FDA, with a PDUFA date in the first quarter of 2024. If approved at that time, FluMist Quadrivalent is expected to be available for self-administration by patients in the U.S. during the 2024 or 2025 flu season.

▲To learn more about the application of cutting-edge technologies in the biopharmaceuticals industry, please long press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.